Video
Dr. Meeks recaps LUGPA panel on optimizing advanced bladder cancer clinic
Author(s):
"There's 3000 patient trials that are either done or going to be done within the next year or 2 in the BCG-naïve setting, and all of them have systemic therapy," says Joshua J. Meeks, MD, PhD.
Video Player is loading.
Joshua J. Meeks, MD, PhD, is an associate professor of urology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In this interview, Meeks recaps a panel discussion on ABCC optimization, which took place at the 2022 LUGPA Annual Meeting in Chicago.
Related Videos
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Expert discusses innovations in single-use ureteroscopes for stones
Perry Xu, MD, on the potential of AI in the endourology space
Amy E. Krambeck, MD, on what’s needed to improve safety, efficacy of HoLEP
The role of preoperative imaging with HoLEP for BPH
Incorporating emerging technologies into HoLEP for BPH
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Related Content
